Plain-English translation of NCT07515040 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This study is testing a newer tool called the AccuSafe transseptal guidewire against the traditional transseptal needle for a specific heart procedure. If you have atrial fibrillation (an irregular heartbeat) and need catheter ablation treatment, you may be eligible. The goal is to see if the AccuSafe guidewire makes the procedure safer, reduces complications, and eliminates the need for X-ray exposure during this part of the treatment.
Atrial fibrillation patients often need a procedure where doctors access the heart through a small puncture in the wall between chambers. The traditional needle method works, but this newer AccuSafe tool may be safer and more precise, potentially reducing radiation exposure for both patients and doctors during the procedure.
You likely qualify if…
You likely don't qualify if…
You will be randomly assigned to receive your catheter ablation procedure using either the new AccuSafe guidewire or the traditional needle method. Both approaches will use ultrasound imaging (called ICE guidance) instead of X-rays to guide the procedure. The study runs from February 2025 to November 2025, and you'll be monitored during the procedure and at follow-up visits to track safety and how well the treatment works.
AI-generated summary from trial data · Jun 19, 2026 · Not medical advice
China